Big pharma partners sign Parkinson’s pact | September 4, 2017 Issue - Vol. 95 Issue 35 | Chemical & Engineering News
Volume 95 Issue 35 | p. 17 | Concentrates
Issue Date: September 4, 2017

Big pharma partners sign Parkinson’s pact

Department: Business
Keywords: Biologics, Parkinson's disease, antibody

AstraZeneca and Takeda Pharmaceutical are joining to develop MEDI1341, an antibody from AstraZeneca intended to treat Parkinson’s disease. MEDI1341 binds to and inhibits α-synuclein, a protein that accumulates in the nerve cells of people with Parkinson’s. Takeda will pay AstraZeneca up to $400 million. AstraZeneca will lead Phase I clinical trials, which are set to start later this year.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment